CSPC Pharmaceutical Group’s Stock Price Soars to 6.99 HKD, Marking a Remarkable 4.02% Uptick

CSPC Pharmaceutical Group (1093)

6.99 HKD +0.27 (+4.02%) Volume: 246.41M

CSPC Pharmaceutical Group’s stock price sees a significant surge, closing at 6.99 HKD, a +4.02% change this trading session with an impressive trading volume of 246.41M. Despite a slight downtrend YTD with a -3.72% change, CSPC (1093) continues to show resilience in the market.

Latest developments on CSPC Pharmaceutical Group

Today, CSPC Pharmaceutical Group‘s stock price saw significant movements following key events with AstraZeneca. AstraZeneca signed a $1.92 billion licensing deal with CSPC, paying $100 million for a preclinical heart disease drug and boosting their cardiovascular pipeline. This deal sets up potential combinations and intensifies their rivalry with Lilly. Additionally, CSPC’s urticaria drug was approved in China, and their CPO301 drug received Fast Track Designation from the US FDA. AstraZeneca’s agreements with CSPC, including licensing rights for a lipid-lowering therapy, have further impacted the stock price as both pharmaceutical companies continue to make strategic moves in the industry.

A look at CSPC Pharmaceutical Group Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, CSPC Pharmaceutical Group has a positive long-term outlook. With high scores in Dividend and Value, investors can expect good returns and stable performance from the company. Additionally, its strong scores in Growth and Resilience indicate potential for future expansion and the ability to withstand economic challenges.

CSPC Pharmaceutical Group Limited, a company known for manufacturing and selling pharmaceutical products such as vitamin C, antibiotics, and generic drugs, also shows promise in its momentum according to the Smartkarma Smart Scores. This suggests that the company is moving in a positive direction and gaining traction in the market. Overall, CSPC Pharmaceutical Group appears to be a solid investment option for those looking for a reliable and growing pharmaceutical company.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma